Manufacturing Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Pharmaceutical TechnologyManufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies. Read full story Post navigation Previous: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trialNext: FDA weighs drug repurposing pathway for underserved diseases Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026